| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/26/2009 | US20090053256 inducing an immune response to a poxvirus in a mammal by administering a composition comprising a nucleic acid molecule comprising nucleotide sequence encoding a variola F8 polypeptide, wherein nucleotide sequence is codon optimized for expression in both a mammalian cell and a bacterial cell |
| 02/26/2009 | US20090053255 Anti-arthropod vector vaccines, methods of selecting and uses thereof |
| 02/26/2009 | US20090053254 Recombinant human alpha-fetoprotein as an immunosuppressive agent |
| 02/26/2009 | US20090053253 Process for the measurement of the potency of glatiramer acetate |
| 02/26/2009 | US20090053252 Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins |
| 02/26/2009 | US20090053251 Dendritic Cell Compositions and Methods |
| 02/26/2009 | US20090053250 Immune Modulating Oligonucleotides in Connection with Chemotherapeutic Measures |
| 02/26/2009 | US20090053249 Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens |
| 02/26/2009 | US20090053248 Compositions and methods for transepithelial molecular transport |
| 02/26/2009 | US20090053247 Biological materials and uses thereof |
| 02/26/2009 | US20090053246 Immunoglobulin fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same |
| 02/26/2009 | US20090053245 Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood |
| 02/26/2009 | US20090053244 Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| 02/26/2009 | US20090053243 Anti-IgSF4 Antibody and Utilization of the Same |
| 02/26/2009 | US20090053242 Thrombopoietic compounds |
| 02/26/2009 | US20090053241 inhibition of platelet derived growth factor receptor-beta (PDGFR beta ) on angiogenesis, and provides for treatment of angiogenesis; |
| 02/26/2009 | US20090053240 Novel Immunoglobulin Insertions, Deletions and Substitutions |
| 02/26/2009 | US20090053239 ACACS As Modifiers of the IGF Pathway and Methods of Use |
| 02/26/2009 | US20090053238 Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations |
| 02/26/2009 | US20090053237 Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections |
| 02/26/2009 | US20090053236 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 02/26/2009 | US20090053235 Use of alpha-toxin for treating and preventing staphylococcus infections |
| 02/26/2009 | US20090053234 Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents |
| 02/26/2009 | US20090053233 Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations |
| 02/26/2009 | US20090053232 Modulation of synaptogenesis |
| 02/26/2009 | US20090053231 Optical Disc Apparatus |
| 02/26/2009 | US20090053230 Anti-ox40l antibodies and methods using same |
| 02/26/2009 | US20090053229 Methods of Treating Conditions Involving Neuronal Degeneration |
| 02/26/2009 | US20090053228 Lawsonia intracellularis subunit vaccines |
| 02/26/2009 | US20090053227 Prostate Specific Genes and The Use Thereof in Design of Therapeutics |
| 02/26/2009 | US20090053226 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 02/26/2009 | US20090053225 Recombinant antibodies against cd55 and cd59 and uses thereof |
| 02/26/2009 | US20090053224 Lox and loxl2 inhibitors and uses thereof |
| 02/26/2009 | US20090053223 Expression-enhanced polypeptides |
| 02/26/2009 | US20090053222 Inhibitors of CD200 such as antibodies or antisense agents for treating cancer, tumor, leukemia |
| 02/26/2009 | US20090053221 Immune response enhancing glucan |
| 02/26/2009 | US20090053220 Methods and compositions for the inhibition of hiv infection of t cells |
| 02/26/2009 | US20090053219 Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| 02/26/2009 | US20090053218 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 02/26/2009 | US20090053217 Human anti-VEGF polyclonal antibodies and uses thereof |
| 02/26/2009 | US20090053216 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of non-hodgkins lymphoma; immunotherapy |
| 02/26/2009 | US20090053215 Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| 02/26/2009 | US20090053214 Antibodies to myelin associated glycoprotein (MAG); neurological diseases/disorders |
| 02/26/2009 | US20090053213 for inflammatory diseases such as rheumatoid arthritis; GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor); |
| 02/26/2009 | US20090053212 Humanized anti-human osteopontin antibody |
| 02/26/2009 | US20090053211 Immunoglobulin with enhanced affinity for Fc gamma R's; immunotherapy; tissue targeted therapy; directed protein evolution |
| 02/26/2009 | US20090053210 Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| 02/26/2009 | US20090053209 Blockade of Pin1 Prevents Cytokine Production by Activated Immune Cells |
| 02/26/2009 | US20090053208 Methods and Systems for Improving Tissue Perfusion |
| 02/26/2009 | US20090053207 Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas |
| 02/26/2009 | US20090053206 Novel synthetic agonists of tlr9 |
| 02/26/2009 | US20090053205 Stabilized immune modulatory rna (simra) compounds |
| 02/26/2009 | US20090053204 Functional Genomic Pore Assay For Mixed Cell Populations |
| 02/26/2009 | US20090053203 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, obesity, cardiovascular, metabolic, neurodegenerative, gastrointestinal, autoimmune, rheumatological and infectious diseases; drug delivery |
| 02/26/2009 | US20090053202 Peptide fragment of LYVE-1 and antibody against the same |
| 02/26/2009 | US20090053201 Using variation in DNA polymerase sequence as diagnostic indicator of adefovir or tenofovir resistance in virus; viricides |
| 02/26/2009 | US20090053200 Method for retarding unhealth manifestations brought by ageing of human beings |
| 02/26/2009 | US20090053199 Stable Dairy Components Effective for Fat Loss |
| 02/26/2009 | US20090053198 Cytokine Induction of Selectin Ligands on Cells |
| 02/26/2009 | US20090053197 Transfer Factor Compositions and Methods |
| 02/26/2009 | US20090053196 Chn-1/Chip-Antagonists For The Treatment Of Muscular Diseases |
| 02/26/2009 | US20090053195 Biomarkers for acute graft rejection |
| 02/26/2009 | US20090053194 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
| 02/26/2009 | US20090053175 Substitute pyrrolidine derivatives |
| 02/26/2009 | US20090053174 Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus |
| 02/26/2009 | US20090053170 Human prostate cell lines in cancer treatment |
| 02/26/2009 | US20090053169 Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same |
| 02/26/2009 | US20090053167 C-, S- and N-glycosylation of peptides |
| 02/26/2009 | US20090053148 Toll like receptor modulators |
| 02/26/2009 | US20090053136 Therapeutic immunoglobulin specific for lymphocyte adhesion protein for killing and/or inhibiting growth of cancer cells |
| 02/26/2009 | CA2734549A1 Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
| 02/26/2009 | CA2697262A1 Compositions of humanized notch fusion proteins and methods of treatment |
| 02/26/2009 | CA2697049A1 Composition and methods of making and using influenza proteins |
| 02/26/2009 | CA2697043A1 Methods and compositions for treatment or prevention of radiation-induced fibrosis |
| 02/26/2009 | CA2697032A1 Activatable binding polypeptides and methods of identification and use thereof |
| 02/26/2009 | CA2696877A1 Novel cellular factor-containing solution compositions |
| 02/26/2009 | CA2696764A1 Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| 02/26/2009 | CA2696761A1 Human c-fms antigen binding proteins |
| 02/26/2009 | CA2696701A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | CA2696691A1 Hypoallergenic molecules |
| 02/26/2009 | CA2696597A1 Foxm1 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696252A1 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 02/26/2009 | CA2696049A1 Formulations of antibodies and fc-fusion molecules using polycations |
| 02/26/2009 | CA2696027A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 02/26/2009 | CA2695532A1 Polymeric linkers containing pyridyl disulfide moieties |
| 02/26/2009 | CA2694476A1 Permissive cells and uses thereof |
| 02/25/2009 | EP2028270A2 Modified recombinant vaccina viruses and uses thereof |
| 02/25/2009 | EP2028190A1 Compounds and methods for therapy and diagnosis of lung cancer |
| 02/25/2009 | EP2028188A1 Hypoallergenic molecules |
| 02/25/2009 | EP2028187A1 Human and mouse targeting peptides identified by phage display |
| 02/25/2009 | EP2027874A2 Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| 02/25/2009 | EP2027873A1 One dose vaccination with mycoplasma hyopneumoniae |
| 02/25/2009 | EP2027867A1 Method and composition for inhibition of tumor growth and enhancing an immune response |
| 02/25/2009 | EP2027866A1 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 02/25/2009 | EP2027865A1 Liposome having lipid membrane containing bacterial cell component |
| 02/25/2009 | EP2027291A2 Methods and compositions for antibody therapy |
| 02/25/2009 | EP2027156A2 Hepatocyte growth factor (hgf) binding proteins |
| 02/25/2009 | EP2027155A2 Human binding molecules having killing activity against staphylococci and uses thereof |
| 02/25/2009 | EP2027150A1 Allorestricted peptide-specific t cells |
| 02/25/2009 | EP2027147A1 Phl p 1 allergen derivative |